Overview

Soluble CD23 Expression in Asthma Patients Treated With OMA

Status:
Terminated

Trial end date:
2007-10-01

Target enrollment:

Participant gender:

Summary

This study involves a FDA approved drug, Omalizumab, used in the treatment of moderate to severe allergic asthma that cannot be controlled by standard treatment. It works on IgE to control the allergic reaction. We are looking at the effects on non-allergic asthma. We hope to prove that Omalizumab will have the same effect on non-allergic asthmatics as it does allergic asthmatics.

Phase:

N/A

Details

Lead Sponsor:

University of Mississippi Medical Center

Collaborator:

Novartis Pharmaceuticals

Treatments:

Omalizumab